In addition to Piper (noted earlier), SunTrust is out defending Clovis Oncology (NASDAQ: CLVS) saying there nothing significantly new in the data. Shares of CLVS are down 13.7% after trading down nearly 30% earlier.

Analyst Comments Trader Talk

Credit Suisse Sees Up to a $7 Cut in Target Price to Clovis (CLVS) if Platinum Resistant/Refractory Removed; M&A Thesis IntactOctober 7, 2016 1:20 PM Clovis (CLVS): Solid Treatment Choice but Maintenance Use Seems Unlikely - StifelOctober 7, 2016 11:16 AM Clovis Oncology (CLVS) Bounces Off Lows, Remains Down 13.8%October 7, 2016 10:44 AM Clovis Oncology (CLVS) Announces Presentation of Encouraging Efficacy, Safety Data on Rucaparib in BRCA Ovarian CancerOctober 7, 2016 8:46 AM Clovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO CongressOctober 7, 2016 8:45 AM